Literature DB >> 2521554

Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin.

Y Yamazoe1, N Murayama, M Shimada, K Yamauchi, R Kato.   

Abstract

The effects of pituitary and pancreatic hormones on the change in hepatic cytochrome P450s were studied in alloxan- or streptozotocin-induced male rats. In two major sex-specific forms, P450-male and P450(6 beta-1), the former was decreased in chronic (5 week) diabetes to only less than one-third of controls and the latter was also reduced in early (1 week) diabetes. In contrast, a main phenobarbital-inducible form, P450b, was enhanced 25- to 30-fold in these diabetic rats. 3-Methylcholanthrene-inducible P448H was also elevated 3-fold in alloxan-induced diabetes. These changes in hepatic contents of P450-male, P450-6 beta-1, and P450b, which are under the regulation of pituitary growth hormone, associated well with the reported results of time-dependent changes in growth hormone levels in diabetes (G.S. Tannenbaum (1981) Endocrinology 108, 76-82), suggesting that the change in growth hormone level is a factor responsible for alterations in hepatic cytochrome P450s. Normalizing effects of insulin on these forms were also studied. Treatment of diabetic rats with insulin reversed the decreased amounts of both P450-male protein and mRNA. Insulin also normalized hepatic contents of P450b, P4506 beta-1, and P448H. However, the treatment of hypophysectomized rats with insulin had no effect, and treatment of diabetic rats with growth hormone or a suppressing agent of somatostatin, cysteamine, showed trivial effects on P450-male and P450b. These results suggest that insulin does not act directly as a substitute of growth hormone, but exerts its effect indirectly through the normalization of a growth hormone-mediated process(es) in diabetic rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521554     DOI: 10.1016/0003-9861(89)90324-x

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  17 in total

1.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

2.  Regulatory sequence responsible for insulin destabilization of cytochrome P450 2B1 (CYP2B1) mRNA.

Authors:  Nhu-Traï Truong; Arlette Moncion; Robert Barouki; Philippe Beaune; Isabelle de Waziers
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

3.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

4.  Effects of insulin treatment on hepatic CYP1A1 and CYP2E1 activities and lipid peroxidation levels in streptozotocin-induced diabetic rats.

Authors:  Gökçe Kuzgun; Rahman Başaran; Ebru Arıoğlu İnan; Benay Can Eke
Journal:  J Diabetes Metab Disord       Date:  2020-08-24

5.  Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver.

Authors:  Maria Konstandi; Jie Cheng; Frank J Gonzalez
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

6.  Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.

Authors:  Yu C Kim; Joo H Lee; So H Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Induction and suppression of renal and hepatic cytochrome P450-dependent monooxygenases by acute and chronic streptozotocin diabetes in hamsters.

Authors:  T L Chen; S H Chen; T Y Tai; C C Chao; S S Park; F P Guengerich; T H Ueng
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

8.  Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes.

Authors:  Susumu Kodama; Chika Koike; Masahiko Negishi; Yukio Yamamoto
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

9.  Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.

Authors:  C Y Ahn; S K Bae; S H Bae; T Kim; Y S Jung; Y C Kim; M G Lee; W G Shin
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 10.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.